Haematology Flashcards
pathogenesis of multiple myeloma
type of haematological malignacy
- caused by malignant proliferation of plasma cells within the bone marrow
- normal plasma cells are derived from B cells
- in myeloma plasma cells produce immunoglobulins of a single heavy and light chain= paraprotein
- although a small number of malignant plasma cells are present in the circulation, the majority are present in the bone marrow
- the malignant plasma cells produce cytokines, which stimulate osteoclasts and result in net bone reabsorption
classification of myeloma
IgG
IgA
light chain only
common incidence of rmyeloma
60-70yrs
it is uncommon
2% of all cancer dx
MGUS
monoclonal gammopathy of insignificance
Monoclonal gammopathy of undetermined significance, or ‘MGUS’, is a benign (non-cancerous) condition. MGUS does not cause any symptoms and is usually diagnosed incidentally when tests are performed to investigate other problems. It does not require any treatment.
In MGUS, abnormal plasma cells in the bone marrow release an abnormal protein, known as paraprotein. MGUS is characterised by the presence of this abnormal protein in the blood and/or urine.
While most MGUS patients have a stable condition which has no effect on their general health, a small proportion of patients will go on to develop a cancer called myeloma.
presenting features of MYELOMA
CRAB
hypercalcaemia-osteoclastic bone resorption
renal failure- due to the paraproteins
Anaemia- reduced RBC erythrocytes production
Bone pain-# spinal cord compression
others
- recurrent infections as reduced normal immunoglobulin production
- AKI
- symptoms of hypercalcaemia-stone bones moans groans thrones
- asymtpomatic
- amyloidosis
- carpal tunnel
- neuropathy
what is the diagnostic criteria for myeloma
- need 2 of the following
1. increased malignant plasma cells in the bone marrow
2. serum and/or urinary protein
3. skeletal lytic lesions
screening inx for myeloma
- serum protein electrophoresis- look for paraprotein in blood
- bence Jones proteinuria
need to do both tests as may have one of other
- if both positive need to do more testing
- if both negative unlikely to be MM so only do further testing if they present with very typical features
confirm inx for myeloma
-bone marrow aspirate and trephine (need >10% clonal plasma cells) -skeletal survery (look for lytic lesions) -bloods check ca, ALKphos, anaemia
morphology of myeloma plasma cells
eccentric nucleus surrounded by a paler area and blue cytoplasm
if no evidence of myeloma related tissue impairment with diagnosis=
smouldering myeloma
if patients have evidence of myeloma with tissue impairment
=multiple myeloma
course time of multiple myeloma
- asymptomatic phase with either MGUS or smouldering myeloma
- once patients become symptomatic they have a certain level of serum light chains or bence jones proteins in urine that can be used to monitor their disease
- most patients respond well to initial therapy and will achieve reduction in paraprotein and some to the point of remission
- remission or plateau phase
6, relapse and remitting with gradually getting worse
management of myeloma
supportive measures
- adequate hydration
- zoledronate for hypercalcaemia
- bone protection
- analgesia for bone pain
- transfusion for symptomatic anaemia
- treatment of bacterial infections- due to hypogammaglobulinaemia
- allopurinol prevent urate nephropathy
- plasmapheresis if necessary for hyperviscosity
emergency complications for myeloma
-renal failure hypercalcaemia hyperviscosity hyperuricaemia spinal cord compression -radiotherapy and bisphosphonates
asymptomatic multiple myeloma management
watchful waiting can be used
<70 yr old myeloma with little or no significant co-morbidties management
intensive chemo approach
1. induction phase dexamethasone plus thalidomide plus PI proteasome inhibitor- borteozmib
2.consolidation phase
autologus peripheral blood stem cell transfer with melphalan
- maintenance phase
immunomodulatory drug thalidomide - relapse
thalidomide plus steroid
non-intensive approach for multiple myeloma management
- induction
thalidomide+ dexamethasone + alkylator eg chlophosphamide/ mephalan
2.maintenace phase
thalidomide
3.relapse
bortezomib plus steroid
how do intensive and non-intensive myeloma management differ
intensive= PBSCT and induction phase use proteasome inhibitor eg bortezomib
non-intensive= no consolidation phase so no PBSCT
poor prognostic factors for multiple myeloma
high B2 microglobulin
low albumin at diagnosis
acute leukaemias myeloid vs lymphoblastic age onset
myeloid= adults lymphoblastic= children
definition of leukaemia
highly aggressive malignancy of haematopoietic stem cells or early progenitor cell
malignant blast cells accumulate in bone marrow and blood
pathogenesis of leukaemia acute
- in acute leukaemia there is a proliferation of primitive stem cells with limited accompanying differentiation, leading to an accumulation of blasts, predominantly in the bone marrow, which causes bone marrow failure
- proliferation of cells that do not mature leading to primitive cells taking up bone marrow space at the cost of normal haematopoietic elements
- eventually this proliferation spills into blood and get blast cells in blood
what conditions can the philadelphia chromosome be found in
CML
ALL
risk factors for leukaemias
ionising radiation
radiotherapy
cytotoxic drugs
retroviruses- HTLV-1 adult T cell leukaemias
diagnosis findings for leukaemia
- blood
- ANAEMIA with normal or raised MCV
- leukopaenia
- sometimes blast cells in the film - bone marrow aspirate and trephine
- hypercellular leukaemic blast cells
- auer rods in cytoplasm indicates it is myeloblastic - immune phenotype
- determine antigens on cells
- ALL blasts are positive for CD19 and CD20 - cytogenic analysis= trisomy 8 can be seen
division of ALL
t or b precursor
AML types
- geentic abnormalities
- myelodysplasia changes
- neoplasms theray related
- myeloid sarcoma
presentation of acute myeloid leukaemia
adult
anaemia= pallor, breathlessness, angina, lassitude, palpitations,
neutropaenia= low neutrophils so get infections- sore throat, resp, perianal, skin, mouth ulcers, fever
thrombocytopaenia= bleeding mucosal - blood blisters, purpura, bleeding gums, prolonged menstrual bleeding, nose bleeds
tissue infiltrates= gum hypertrophy
bone pain
presentation of acute lymphoblastic leukaemia
child
-bone marrow failure
anaemia= pallor, breathlessness, angina, lassitude, palpitations,
neutropaenia= low neutrophils so get infections- sore throat, resp, perianal, skin, mouth ulcers, fever
thrombocytopaenia= bleeding mucosal - blood blisters, purpura, bleeding gums, prolonged menstrual bleeding, nose bleeds
tissue infiltrates= lymphadenopathy, testicular swelling, hepatomegaly, splenomegaly
-bone pain
management conservaitve acute leukaemias
- if very elderly or serious co-morbidities
- supportive treatment
- can give low intensity cytosine arabinoside
immediate management of acute leukaemias
- treat existing infection
- correct anaemia with transfusion
- control bleeding with platelet transufsion
- central venous catheter insertion
- assess tumour lysis risk and start prevention- allopurinol or rasburicase
stages of acute leukaemias management
- remission induction -combination chemotherapy after which patient can be in bone marrow hypoplasia and need intensive support
- remission consolidation- in remission but residual disease attacked by therapy
- remission maintenance- consolidate
chemotherapy for acute leukaemias ALL
- intensive
- remission induction: vinicristine, prednisolone, L asparaginase-pegaspargase +danorubicin
- consolidation= danorubicin, methotrexate
- maintenance= mercatopurine, methotrexate, vinicristine and prednisolone
- intrathecal methotrexate for CNS prophylaxis
- stem cell transplant
ALL what prophylactic treatment can be given for CNS
cranial irradiation
intrathecal methotrexate
AML chemotherapy
induction: danuroubicin
consolidation: cytarabine, amsacrin
what should be given to acute leukaemias if philadelphia positive
IMATINIB
PROGNOSIS ALL in children
> 90%
what is acute promyelocytic leukaemia
translocation in 15-17
treat with Vit A compound
assoc. to DIC
child with unexplained hepatosplenomegaly or unexplained petechiae should
refer urgently to specialist- ALL
child with pallor, persistent fatigue, unexplained fever
consider ALL
need urgent FBC <48hrs
A 4-year-old girl presents with lethargy, dyspnoea, fever, and bruising. On examination she has hepatosplenomegaly. Chest x-ray shows a mediastinal mass and pleural effusion.
ALL
A 58-year-old man presents to his primary care physician with increasing tiredness, accompanied by bruising on his legs. He also complains of aching bones. He has no previous illnesses. On examination, he is pyrexial and pale, has bony tenderness over the sternum and tibia, and has petechiae on his legs. There are no palpable lymph nodes. He has crepitations at the left base. The liver and spleen are not palpable.
AML
A 45-year-old woman presents to the emergency department with nausea, vomiting, and confusion. She has a history of low back pain of 6 months’ duration and increasing sciatic pain in the last 2 weeks. On physical examination, the patient is pale and dehydrated with bone tenderness in the lumbar region. Neurological examination reveals an upgoing plantar reflex on the left with intact power in all muscle groups and at all joints. Magnetic resonance imaging reveals an L5 compression fracture. This is associated with hypercalcaemia and renal insufficiency.
Multiple myeloma
A 55-year-old man has had routine physical examinations for several years and has always been healthy, does not smoke, and has no history of pulmonary disease. His primary care physician has noted a gradually increasing haemoglobin level over the past few years (to a current level of 195 g/L [19.5 g/dL]), mild leukocytosis, and mild thrombocytosis. He has frequent episodes of facial flushing that are associated with slight headaches and a feeling of fullness in his head and neck. He has noted intermittent burning, stinging, and tingling sensations in his fingertips. He has recurrent, often severe, pruritus that is exacerbated by taking a hot bath. On examination, he has a red face and neck and the spleen is mildly enlarged.
polycythaemia vera
72 year old woman reports fatigue, night sweats, 4.5 kg (10 lb) weight loss, abdominal discomfort, and progressive dyspnoea on exertion. Laboratory results reveal a white blood cell count of 6.2 x 10^9/L (6200/microlitre) with an absolute neutrophil count of 2.2 x 10^9/L (2200/microlitre), an absolute lymphocyte count of 2.4 x 10^9/L (2400/microlitre), and 0.36 x 10^9/L monocytes (360 monocytes/microlitre); a haemoglobin (Hb) of 60 g/L (6 g/dL) with a mean corpuscular volume of 86; a platelet count of 96 x 10^9/L (96 x 10^3/microlitre) and a reticulocyte count of 0.6%, with an absolute reticulocyte count of 14.1 x 10^9/L (14.1 x 10^3/microlitre). The peripheral blood smear shows occasional teardrop-shaped red blood cells, and erythroblasts and myelocytes. on examination there is splenomegaly and they have a dry tap
PMF
A 54-year-old man presents to his primary care physician with a 2-month history of fever, malaise, and weight loss. He also reports frequent epistaxis, abdominal fullness, and early satiety. On examination, he is found to have splenomegaly.
CML
A 62-year-old man presents to his primary care physician for an annual physical. He denies any complaints such as fever or chills, weight loss, or fatigue. Of note, his blood tests show an elevated WBC count. The WBCs are predominantly lymphocytes, with a differential of 80% lymphocytes and an absolute lymphocyte count of 75 x 10⁹/L (75 x 10³/microlitre).
CLL
25 yr old male
painless unilateral neck lumps
6 month history
He denies recent upper respiratory tract infections, fevers, night sweats, or unintentional weight loss. He is otherwise healthy. Social history and family history are unremarkable. On examination he is afebrile with normal vital signs. Pertinent findings include a 3-cm, firm, round, non-tender, mobile mass in the mid-right neck. There is no other peripheral lymphadenopathy. Liver and spleen are not enlarged.
hodgkin’s
A 56-year-old woman presents with a painless right neck lump that has been slowly enlarging for the last 2 years. She denies fevers, night sweats, or weight loss. Physical examination reveals bilateral cervical and axillary adenopathy and a palpable spleen.
non-hodgkin’s
pathology of chronic leukaemias
in chronic leukaemias the malignant clone is able to differentiate resulting in an accumualtion of more mature cells aka from the myelocytic and lymphocytic progenitor cells
- myeloid relates to RBC, granulocytes, monocytes and platelets
- lymphocytes relates to T and B cells
diagnosis chronic leukaemias
- abnormal blood count- raised WCC
- examination of bone marrow- immunophenotyping
chronic myeloid leukaemia pathology
- 30-80 yrs
- proliferation of all haematopoietic lineages, but predominantly granulocytic series- myeloid
- philadelphia chromosome
how is the philadelphia chromosome formed
- reciprocal translocation c22 and c9
- shortened chromosome 22 =philadelphia
- puts BCR and ABL next to each other which makes tyrosine kinase so get uncontrolled proliferation
phases of CML
chronic phase
-disease is responsive to treatment and easily controlled
accelerated phase
-disease control more difficult
blast crisis
- in which the disease transforms into an acute leukaemia either myeloblastic or lymphoblastic which is relatively refractory to treatment
- cause of death in majority of patients
- cant predict it
chronic vs acute leukaemias
chronic leukaemias is due to proliferation of myeloid or lymphocyte cells- over months to years - leukocytosis plus hepatosplenomegaly - marrow failure is later on
acute leukaemias is due to proliferation of blast- weeks days - with features of marrow failure
presentation CML
older patient
late middle age
abdominal discomfort and splenomegaly
most are asymptomatic
also can be hyperviscoisty- mucosal bleeding, SOB, visual changes, new neurology
thrombosis state
lethargy, weight loss, abdo discomfort, gout sweating
inx CML and results
like other myeloproliferative disorders blood -neutrophilia (baby neutrophils) -normocytic normochromic anaemia -thrombocytosis sometimes -raised WCC -LDH and urate can be high due to increased turnover
blood film
myeloblast to mature neutrophils present
predominant are neutrophils and myelocytes
also increase in eosinophils and basophils
- if it progresses to an accelerated phase then primitive cells increase
bone marrow
-confirm diagnosis
chromosome analysis for philadelphia chromosome
management of chronic phase CML
- give tyrosine kinase inhibitors= imatinib
- take bone marrow sample at 6 months to confirm
- 3 monthly blood BCR ABL mRNA aim to reduce levels
2nd line switch to a different TK inhibitor
3 rd line= allogenic HSCT haematopoietic stem cell transplant
management of accelerated phase treatment CML
TKI therapy
allogenic HSCT
hydroxycarbamide in older patients
CLL presentation
older
asymptomatic
often diagnosed on isolated lymphocytosis
50% have lymph nodes, splenomegaly
-anaemia, infections, painless lymphadenopathy, systemic symptoms, such as night sweats, weight loss
inx CLL
blood
- high lymphocyte count -isolated +++
blood film
-mature lymphocytosis >5
blood sample-flow cytometry
blood test-immunophenotyping
-monocloanal B cells express CD19 OR 23
t cell antigen CD5
bone marrow exam not essential but can be helpful
also can do coombs test and hypogammaglobulinaemia
assoc. autoimmune phenomena to CLL
- ITP - petechiae development
- autoimmune haemolysis
management of stage A CLL
watch and wait
no specific treatment
doesnt change life expectancy
treat if evidence of bone marrow failure
stage b and c or a with bone marrow failure
CLL management
Fludarabine with alkylating agent cyclophosphamide and rituximab if <70 fit and TP53 mutation
if older and less fit use rituximab with bendamustine
new inhibitors of B cell receptor= ibrutinib for relapsed CLL and TP53 mutation
lymphoma pathology
cancer of lymphocytes in lymph nodes and extra-nodal areas eg spleen, liver, bone marrow
-neoplasma arise from lymphoid tissue
presentation of lymphoma
-swelling lymphadenopathy
>1cm, painless, persistent and not reactive
often in neck, axillaem inguinal, internal
- internal swelling can lead to mass effect eg compression on airways, bowel, ureter, SVCO, dysphagia
- organomegaly: hepatosplenomegaly
- constitutional B symptoms- fever, night sweats, weight loss
- marrow failure if diffuse marrow involvement
inx lymphoma
FBC
- only abnormal if lymphoma is also in the marrow (then can get marrow failure)
- anaemias
- raised ESR in hodgkin’s
Tissue lymph node biopsy
CXR
PET-CT
staging
- CT staging CAP
bloods
- LDH marker of cell acitivty
- urate idea of risk of tumour lysis syndrome
Excision biopsy - a whole lymph node biopsy is the gold standard dx
tissue lymph node biopsy for non hodgkin
follicular lymphoma
hodgkin lymphoma cell
reed sternberg cell
types of lymphoma
hodgkin non hodgkin -b cell -t cell -high grade eg diffuse large B cell lymphoma low grade eg follicular
high grade non-h means
divides rapidly
present for a matter of weeks before dx
can be lifethreatening
low grade non h means
divides slowly
present for many months before dx
behave in an indolent fashion
hodgkin lymphoma features
younger people reed sternberg b cell aggressive but highly curable painless, rubbery lymphadenopathy, asymtpomatic cough, fever, haemoptysis, dyspnoea b symptoms
management of hodgkins
ABVD doxorubicin, bleomycin, vinblastine and darcarbazine
combined with radiotherapy
non-hodgkin cause
-no single causative abnormality described but can be linked to -HIV EBV HTLV-1 MALT lymphoma to h.pylori
presentation of non-hodgkin
can be widely disseminated at presentation including extranodal sites if high grade
-systemic upset
-hepatosplenomegaly
SVCO if compression or ascites
additional inx for non hodgkins
bone marrow aspiration and trephine immunophenotyping of surface antgens distinguish t and b cells HIV hep b and c testing immunoglobulin determination
management low grade NHL
majority preset with advanced stage disease and will run a relapsing and remitting course
-asymptomatic can be watchful waiting
options -radiotherapy chemotherapy monoclonal antibody kinase inhibitors transplantation
management high grade NHL
chemotherapy
monocloanal antibody therapy
radiotherapy
HCST
management follicular lymphoma
stage 1 and 2
vs
stage 3 and 4
radiotherapy in stage 1/2
stage 3/4
-if symptomatic- chemotherapy using R-CVP
rituximab, cyclophosphamide, vinicristine, prednisolone
-asymptomatic watchful waiting or solely use rituximab
CHOP treatment for non hodgkin’s lymphoma
cyclophosphamide
doxorubulin
vinicristine
prednisolone
-young man
asymmetrical and painless superficial lymphadenopathy
alcohol induced nodal pain
HL
late middle age
lymphadenopathy
non hodgkin’s
A 70-year-old coal miner presents with 3 weeks of haematuria and bruising. He is normally fit and well. He is on no medications. His results reveal: Hb 9.0 WCC 11 Pl 255 PT 16 (normal) APTT 58 (increased) Thrombin time 20 (normal).
factor 8 acquired haemophilia
A 33-year-old female is admitted for varicose vein surgery. She is fit and well. After the procedure she is persistently bleeding. She is known to have menorrhagia. Investigations show a prolonged bleeding time and increased APTT. She has a normal PT and platelet count.
von willebrand factor
complications of CLL
-anaemia
hypogammaglobulinaemia (recurrent infection as low Ig)
warm autoimmune HA
Transform to high grade lymphoma- Richter transforamtion
what is Richter transformation
transformation CLL to non hodgkin lymphoma
- lymph node swelling
- fever without infection
- weight loss
- night sweats
- nausea
- abdominal pain
what are the myelproliferative neoplasms
disorders characterised by clonal proliferation of malignant bone marrow cells
which are the 4 myeloproliferative neoplasms
- essential thrombocytosis
- polycythaemia vera
- CML
- myelofibrosis
essential thrombocytosis pathology
megakarocyte proliferation results in an over-production of platelets
features of essential thrombocytosis 4
- platelet count >600
- thrombosis and haemorrhage can be seen
- burning sensation in hand
- JAK2
treatment of essential thrombocytosis
- hydroxyurea- hydroxycarbamide lowers platelets
- Interferon alpha- low dose aspirin
polcythaemia vera inx findings
- raised RBC
- often increase neutrophils and platelets, basophils also
- JAK2 mutation
- Iron studies
- renal and liver
features of polycythaemia vera
over 60 hyperviscosity-thrombosis pruritus splenomegaly haemorrhage plethoric appearance HTN decreased ESR
treatment of polycythaemia vera
- venesection= 1st line
- aspirin
- hydroxyurea
prognosis of polycythaemia vera 3
- thrombotic events
- 5-15% progress to myelofibrosis
- 5-15% progress to acute myeloid leukaemia
myelofibrosis pathology
- hyperplasia of abnormal megakeraryocytes
- resultant release of platelet derived growth factor is thought to stimulate fibroblasts
- leads to extensive scarring in bone marrow
features of myelofibrosis 3
- insidious fatigue and weight loss
- splenomegaly
- elderly person with symptoms of anaemia
investigation findings of myelofibrosis 5
- anaemia
- increased WCC and platelet count
- “tear drop” poikiocytes on blood film
- “dry tap” therefore trephine biopsy needed
- increased LDH and urate
cause of primary myelofibrosis
can be progression from polycytheamia vera or Essential thrombocytosis
causes of plasma cell dyscrasias 4
MGUS monoclonal gammopathy of undetermined significance
multiple myeloma
amyloidosis
plasmacytoma
how do we know that haematological malignancies arise from a single cell
clonality
CML pathology
- reciprical translocation of c 22 and c9
- get shortened 22 with bcr next to abl which creates mRNA for tyrosine kinase activity
- philadelphia chromosome
concerning features of a lymph node
>1cm not mobile rubbery not tender persistent
types of blood groups
o and a are commonest
o, a, b and AB
negative or positive
if o what blood is compatible
only o
if ab what blood is compatible
all
if b what blood is compatible
only b and o
if o negative what blood is compatible
only o negative
what does rhesus positive mean
means the red cell carry D antigen are D poisitive
85% of the population
D negative needs D negative
why do rhesus negative need to receive rhesus negative
- rhesus negative can make anti-D if they are exposed to D positive cells through transfusion or pregnancy
- can cause haemolysis on future exposure
so rhesus o negative can only receive o negative hence its given in rhesus scenarios
monitoring on blood transfusion how often
temperature and blood pressure every 30 mins
types of blood products
-whole blood-rarely used
-red cells
-platelets
fresh frozen plasma
cryoprecipitate
prothrombin complex
target haemoglobin for anaemia transfusion
when to transfuse
80 Hb for acute coronary syndrome
70 Hb for without acute coronary syndrome
target haemoglobin for after transfusion
acute coronary syndrome= 80-100
without= 70-90
target when to transfuse platelets
- if bleeding or
- count <20 x10^9
how much should 1 unit of platelet increase platelet count
by 20x10^9
if surgery is planned at what platelet level should you get advice from haeamtology
<100
fresh frozen plasma indication
-used to correct clotting defects eg DIC, warfarin overdose, liver disease, thrombotic thrombocytopaenic purpura
types of plasma products
FFP
cryoprecipitate
prothrombin complex concentrate
indication for FFP
clinically significant bleeding but not major haemorrhage with clotting defects/ abnormal coag result
what is cryoprecipitate
factor 8 vWF, fibrinogen and factor 13
when is cryoprecipiate indicated
patients without major haemorrhage who have a
- clinically significant bleed AND
- fibrinogen <1.5
prothrombin complex concentration indication
- for emergency reversal of warfarin in patients with either
1. severe bleeding or
2. head injury with suspected intracerebral haemorrhage
major haemorrhage
when is human albumin solution indicated
replace protein in hypoprotein aemic patient eg liver disease who is fluid overload
or abnormal paracentesis
definition of massive blood transfusion
replacement of an individuals’ entire blood volume in 24hours
complications of massive blood transfusion
low platelets low calcium low clotting factors increased potassium hypothermia
acute haemorrhage blood product choice
use crossmatched if possible
but if not possible then use o negative
change to cross match as soon as possible
cautions for transfusing a patient with heart failure
give each unit over 4 hours with furosemide with alternate units
check for increased JVP and basal lung crackles
consider CVP line
how is autologous blood transfusion done
-patients have their own blood stored pre-op for later use
give
- EPO to increase yield
- intraoperative cell salvage with re-transfusion
definition of mild febrile reaction to blood transfusion
defined as a temperature of 38 and a rise of between 1-2 degrees from pre-transfusion values
but no other symptoms or signs
how is the risk of febrile reactions to blood transfusions now reduced
leuco-depletion
pathology of febrile reactions
reaction to white cells or cytokines released from white cells
patient already has antibodies to the WCC
or due to cytokines
definition of mild allergic reaction
-transient flushing urticaria or rash, sometimes with a respiratory wheeze
pathogen of allergic transfusion reactions
due to an allergen in the donor’s plasma
occurs more frequently in patients with other allergies and atopy
what products tend to cause allergic transfusion reactions
plasma or platelets transfusion
what products tend to cause febrile transfusion reactions
red cells and platelets
not usually plasma
definition of moderate febrile transfusion reaction
rise of temperature of 2 degrees or more, or fever of 39degrees or rigors, chills and other inflammatory symptoms/ signs such as myalgia or nausea
definition of moderate allergic reaction
-wheeze or angioedema with or without flushing/ urticaria
but without resp compromise or hypotension
definition of severe transfusion reaction febrile
reaction that fulfills the criteria of moderate and requires immediate medical attention or leads to admission or prolongs hospital stay
definition of severe allergic reactions
causing respiratory compromise or circulatory compromise which requires urgent medical intervention
or
anaphylaxis
acute transfusion reactions <24 hrs
acute haemolytic allergic/ anaphylaxis infection febrile non haemolytic respiraotry - TACO/ TRALI
delayed transfusion reaction >24hrs
delayed haemolytic
infection
transfusion vs graft host disease
post transufion pupura
responding to a transfusion reaction
- stop transfusion and call senior
- treat the patient symptomatically -antih-paracetamol
- if collapsed call for help and A to E
- inx the cause: set of observations, check right blood and right patient, check bag, culture, x-ray
- seek haematologist help if doesnt settle
- keep the patient informed
- report locally and externally SHOT reported
acute haemolytic reaction pathology
ABO mismatch
RBC antibody IgM reacts with RBC causing
-intravascular haemolysis= RBC directly
-extravascular haemolysis= destroys spleen
antibodies cause the RBC to agglutinate and complement too RBC
cause of acute haemolytic reaction
usually due to failure of identification and checks
acute haemolytic transfusion reaction clinical presentation
-agitated chills abdominal pain- loin pain dizzy blood pressure collapse can get fever dark urine renal failure DIC -bleeding
What is TRALI
transfusion related acute lung injury
presentation of TRALI
- severe breathlessness and hypoxia within 6 hours of transfusion
- consider in patient not responding to pulmonary oedema treatment
pathology of TRALI
- transfusion of donor anti-white cell antibodies reacting with the patient’s white cells
- white cells stick in the pulmonary capillaries and cause lung damage
- white cell antibodies occur in female donors because of previous pregnancy
how is TRALI rates reduced
- for FPP or platelets either come from a male donor or from a female donor who has been screened for anti white cell antibodies
- mostly male donors
inx findings TRALI
-pulmonary bilateral infiltrates
management of TRALI
- supportive therapy
TACO is
transufsion associated circualtory overload
-pulmonary oedema
usually at end of transfusion
reducing risk of TACO
- give only one unit at a time and reassess
- calculate dose by body weight
- monitor vital signs closely
- measure fluid balance
- reduce rate of transfusion
- give diuretics with transfusion
presentation of TACO
acute respiratory distress due to acute pulmonary oedema occurring during or within a few hours of transfusion
who is at risk of TACO
-very old and very young
renal impairment
heart failure
what is the commonest cause of transfusion related death
TACO
management of TACOg
give diuretics
call senior stop
usually procedure
timing and acute transfusion reaction order
anaphylaxis 15 mins
acute haemolytic reaction within minutes collapse
TACO- during or just after
TRALI- 6 hrs after
delayed haemolytic transfusion reaction HTR pathology
rare type of reaction
- usually seen in patients who have developed red cell antibodies in the past from transfusion or pregnancy
- ALLOMUNISATION: formation of IgG red cell antibodies that form in response to a previous transfusion or pregnancy
- If the patient has another transfusion with RBCS expressing the same “foreign” antigen the immune antibodies cause RBC destruction
- the antigen antibody complex does not destroy the red cell until it reaches the spleen or other macrophages within the reticulo endothelial system = EXTRAVASCULAR HAEMOLYSIS
-SORT OF RED CELL ANTIBODIES THAT CAUSE A DHTR are anti d, anti c, anti k, anti Fy and anti Jk
importance of cross match
-if a red cell antibody is identified, blood that is negative for that antigen is selected for crossmatching- if the antibody screen misses the antibody it can be picked up by the crossmatch
what does a group and screen do
it tells you the blood group and the antibody screen
but can miss specific antibodies as it only expresses all the red cell antigens that are “clinically significant”
what causes a delayed haemolytic reaction if blood given is crossmatched (aka should pick up all antibodies)
- a new antibody has formed
- an alloantibody was missed
what does a crossmatch do
tests you blood directly with the selected donor blood to make sure compatible
presentation of DHTR
several dayss to two to three weeks after -fever falling haemoglobin or a rise in HB which is less than expected jaundice haemoglobinuir a
immunological transufsion reactions
acute haemolytic- naturally occurring IgM antibodies to specific groups
delayed haemolytic- from previous transfusion/ pregnancy
TRALI- donor white blood cell antibodies
febrile non haemolytic- patient white blood cell antibodies
graft vs host
PTP
non immunological transfusion reactions
mild mod severe allergy
infective
physiological- TACO
how often are observations done during a blood transfusion
before
after 15 mins
and at end of transfusion
management of febrile non haemolytic transfusion reaction
stop transfusion and call senior set of observations determine severity give paracetamol follow procedure
mild allergic reaction treatment
antihistamines
acute haemolytic reaction treatment
stop transfusion call senior
IV access and transfer to ITU-needs renal support
anaphylaxis treatment
adrenaline and antihistamines
bacterial contamination treatment
cultures and broad spec abx
TACO treatment
diuretics
TRALI treatment
oxygen and resp support
features of haemolysis
fall in hb
rise in bilirubin uncongugated
rise in LDH
blood film showing red cell spherocytosis
viral transmitted infection - how is the risk of this reduced
donor health check questionnaire
viral antibody testing
antigen testing
nucleic acid testing
what viruses are checked for
antibody HCV, HIV, HTLV1
antigen HBV
nucleic acid HCV and HIV and HEV
tranfusion assoc. graft versus host disease TA GVHD pathology
-engraftment of donor lymphocytes because the patient is immunosuppressed or the HLA is similar
causes multi-organ failure and death in all cases
how is TA GVHD risk reduced
IRRADIATED cellular blood components for all patients who are immunosuppressed
indications for irradiation
-immunosuppressed
severe T cell immunodeficiency
Hodgkins
HLA similar- blood from 1st or 2nd degree relatives or HLA matched platelets
other components: granulocytes, blood for intrauterine transfusions
treatments immunosuppressed- meds and stem cell transplant
presentation of transfusion assoc. graft vs host disease
-4 to 30 days after immunosuppressed patient or HLA similar increased temp erythroderma desquammation diarrhoea abnormal LFT
management of TA vs GHD
steroids
but always fatal
how often can you donate blood and what ages
donate every 12 weeks
from 17 yrs to (66 unless good health no upper limit)
stages of blood donation 6
- make sure fit and well and something to eat
- donor health check quesion about health and recent travel
- give consent
- finger prick test make sure not anaemic
- lie back clean and needle inserted
- blood giving takes 5-15 minutes
after blood donation advice 4
- leave dressing on arm for 2 hours
- rest reover and dont do strenuous exercise for a few hours
- donors are asked to call up donor care line for up to 14 days post donation if feel unwell/ doubts
- immediate medical attention advice
what testing is done on donated blood products 4
- first 30 ml blood is diverted into a pouch to reduce risk of bacterial contamination
- donation checked for ABO and D group
- mandatory viral testing
- discretionary test depending on travel hx and ethnic orgin
what are the mandatory blood tests6
hep b hep c hep e HIV HTLV1 syphilis
discretionary test on blood donated
cmv
malaria
west nile virus
HbS
HbS blood donation test is for
sickle cell patients
-needs to be done for blood for a sickle cell patient
as sickle cell patients should NOT receive blood from carriers for sickle cell disease
the whole blood process
- whole blood is collected into an anticoagulant- CPD
- unique 14 digit number given
- leucocyte depletion by filtration remove WC
- centrifuge to separate out the remaining components
- red cells re-suspended in SAG-M
- platelets made by pulling from four donors into a satellite bag and then re-suspended in PAS
- FFP made by plasma into satellite bags -but all plasma from female donors is discarded due to risk of white cell antibodies from pregnancy/ transfusion TRALI
what anticoagulant is whole blood put into
citrate phoshate dextrose
what are red cells suspended in after centrifuge
SAG-M sodium adenin mannitol glucose
what are platelets suspended in after being pooled from 4 donors into a satellite bag
PAS platelet additive solution with a bit of plasma to reduce risk of allergic reactions
what is a RAD sure label
used to label if irradiated or not
-done by a chemical in the label which turns black on irradiation if the blood undergoes irradiation
UK specification for leucocyte depletion
-LD whole blood takes place by filtration within 24hrs from donation but always by D2
some white blood cells may still be present hence need for irradiation
what steps means that CJD does not need to be tested for in blood donations
- patients who have received a blood transfusion since 1980 cannot donate blood again
- leucocyte depletion
- UK plasma not used for fractionation
- imported FFP for all patients born after 1996
shelf life red blood cells
35 days
storage temperature for red blood cells and where
2-6 degrees
only in blood fridge never any other
how long if out of the blood fridge till red blood cells have to be discarded
30minutes